Soluble suppression of tumorigenicity associated to post-procedural no-or-slow-reflow phenomenon in ST-elevation myocardial infarction

Abstract Background Over the last decades, prognosis for patients with ST-elevation myocardial infarction (STEMI) has improved due to primary percutaneous coronary intervention (pPCI). However, no-or-slow-reflow phenomenon after pPCI constrains this benefit. Suppression of tumorigenicity (sST2) is released from vascular endothelial cells in response myocyte stretch and increased sST2 level initial phase STEMI a useful prognostic biomarker predicting mortality heart failure (HF). Purpose To explore association post-procedural STEMI. Method During 1-year period 2015/2016, study included consecutive two centers who underwent acute angiography (CAG). Blood samples including levels were collected at admission before and/or revascularization. Post-procedural flow was assessed according thrombolysis (TIMI) classification We divided into groups: TIMI 0,1 2 as no-or-slow-reflow, 3 normal reflow. Both troponin I T used therefore combined grouped 10th percentile levels. The between explored using multiple logistic regression adjusted age, gender, hypercholesterolemia, diabetes, hypertension, cardiogenic shock, time onset symptoms CAG, Results In total, 1,789 verified available analysis. Of these, 1,693 (94.6%) classified reflow 96 (5.4%) no-or-slow-reflow. proportion male sex similar (1,253 (74%) vs 67 (70%), p=0.36) groups. No-or-slow-reflow older (median 68 years (IQR 57–75) median 63 54–72), p=0.02) more likely develop shock (22 (23%) 146 (8.6%), p<0.001). groups (no-reflow: 5.50 (2.00, 8.00) reflow: 5.00 (3.00, 7.00), p=0.38). model, independently associated no-or-slow-flow (two-fold increase: OR 1.37 (1.09, 1.70, p=0.006)). Conclusion STEMI, phenomenon. Funding Acknowledgement Type funding sources: Public hospital(s). Main source(s): Righospitalets Forskningsfond AND Lundbeck Foundation